Logo
G

Greywolf Therapeutics

51 employees

Many cancers and other diseases are caused, or resist treatment, because T cells can't recognize or target cells correctly. We're progressing first-in-class antigen modulators through the clinic, developed to treat disease by controlling T cell activation. Our technology modulates antigen presentation, flicking a switch inside cells to alter their appearance to the immune system. This approach marks a fundamental shift in how we treat people living with autoimmune disorders, cancers and infectious diseases.

Basic info

Industry

Biotechnology Research

Sectors

Biotechnology Research

Date founded

2017

FAQ